Synthetic Phenols, Antidepressants and Anesthetics with Carvacrol and Propofol Derivatives.

Synthetic Phenols, Antidepressants and Anesthetics, with Carvacrol and Propofol Derivatives as an Example.
Independent researcher Yaroslav Grigorievich Zaitsev 0000-0002-0069-2997

Natural and synthetic phenols, terpenes with minimally expressed aliphatic moieties, and related structures can be physiologically active enough for pharmacological use, as demonstrated by Propofol, a potent anesthetic with a unique structure and pharmacological properties.

Propofol is a potent GABA receptor activator, while Carvacrol is a mild dopamine and serotonin regulator and may have mild antidepressant properties.

Propofol's activity may be due to two isopropyl groups, one of which can mimic the carboxyl group of GABA, while the other mimics the leucine radical of enkephalins, attaching to the opioid allosteric site on the GABA receptor, as occurs with some benzodiazepine antipsychotics, such as Pregabalin or Alprozolam.

Carvacrol's activity may be due to the ability of the methyl group of dopaminergic and serotonergic molecules to mimic and displace the aromatic ring. This causes the phenethylamine to be read by the receptor as tryptamine. Carvacrol does not contain hydrophilic radicals that mimic the amino group, but it may nonetheless be involved in catecholamine regulation, reuptake blockade, and possibly direct effects on dopamine and serotonin receptors.Like eugenol, carvacrol may exhibit minimal activity, and its beneficial properties could be enhanced and adjusted, similar to those of Propofol. Propofol is a unique drug with no direct analogues, and the development of a number of alternatives could potentially open a whole range of possibilities for clinical application.

Thus, working with the design of a virtually unexplored group of centrally active phenol derivatives, raising awareness to a rational, actionable level. It is likely possible to tap into a hidden layer of pharmacological potential and reveal the range of possibilities of a previously non-existent group of physiologically active substances.

The design of Carvacrol derivatives was aimed at creating gentle, high-quality, and safe neuromodulators, antidepressants, and nootropics. The design of Propofol derivatives was aimed at creating a range of alternatives: drugs that are more potent at lower doses, drugs with more pronounced allosteric pro-opioid activity, drugs with a pharmacological profile similar to benzodiazepines - drugs less extreme than Propofol, acting at lower doses, and with a more functional pharmacological profile.

Examples of derivatives: